|Bid||41.8400 x 1000|
|Ask||41.8700 x 800|
|Day's Range||40.80 - 42.54|
|52 Week Range||16.74 - 59.25|
|Beta (3Y Monthly)||2.51|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
It’s one of the world’s fastest growing plants—a separate species of the cannabis sativa genus that, due to its 0.3% tetrahydrocannabinol (THC) content, makes it literally almost impossible to get high from smoking it. Just weeks ago, U.S. President Trump signed the 2018 Farm Bill into law. The newly revamped bill legalizes industrial hemp in the U.S., and in doing so not only makes hemp and CBD eligible for lucrative federal crop insurance, but also removes CBD from the Controlled Substances Act.
Canopy Rivers Inc. (the “Company” or “Canopy Rivers”) (RIV.V) today announced that Narbe Alexandrian has been appointed as President of the Company, effective immediately. In this role, Narbe will lead the corporate development initiatives as well as manage the day-to-day business of the Company. “I believe that the team at Canopy Rivers has developed one of the most attractive and compelling platforms in the cannabis industry today,” said Narbe Alexandrian, newly appointed President of Canopy Rivers.
The marijuana tailwind has been great for the entire sector, but the most well-known companies got there for a reason. It hasn't received the same level of attention, but the neurology sector is seeing a similar tailwind. This is an immense $6 billion market opportunity in the coming years, and these companies are commanding big market valuations as a result.
Ryan McQueeney covers the latest Brexit news and Snap's executive exodus. He also recaps earnings results from Goldman Sachs, Bank of America, and United Air Lines. Later, he discusses a busy week for deals in the cannabis industry.
CORAL GABLES, FL / ACCESSWIRE / January 16,2019 / Marijuana stocks have been anything but safe over the course of the past year to two years, during the course of which top players in the cannabis industry saw huge boosts in investor interest. With the new year in full swing, Leafbuyer Technologies Inc (LBUY), New Age Beverages Corp (NBEV), Canopy Growth Corp (CGC) (WEED.TO), and Tilray Inc (TLRY) are 4 pot stocks that could make moves on Wednesday. The Company has been referred to as the "Priceline of Pot" by several sources, and similarly to the site which provides travel deals, Leafbuyer is the most comprehensive online source for cannabis deals and specials.
The end of last year brought something not seen in a while--a bear market. As a result, many investors were reeling as stock prices--particularly in the tech industry--massively declined. However, when stocks decline, there is one silver lining that benefits cash-rich investors: cheap stocks. Many of the best stocks are now trading at low prices. Moreover, when companies with cheap stocks maintain or improve their growth rates, many investors often look to buy their shares. As we begin the new year, the following cheap stocks have those characteristics, leaving them well-positioned to skyrocket in the coming months and years. * 10 Growth Stocks With the Future Written All Over Them InvestorPlace - Stock Market News, Stock Advice & Trading Tips ### Cheap Stocks to Buy: Bank of America (BAC) More than ten years after the financial crisis, Bank of America (NYSE:BAC) is again on a list of cheap stocks. BAC has come a long way since it fell to $2.50 per share at the height of the crisis. Now, it trades at almost $29 per share. Moreover, it resumed annual increases of its dividend in 2014. Today, it returns 60 cents per share of dividends to its shareholders each year, yielding about 2.1%. However, the forward price-earnings ratio of about ten is what really makes BAC one of the best stocks. The multiple is well below the stock's five-year average of about 19. Also, companies whose stocks have single-digit PEs rarely generate double-digit profit increases, but BAC is in that category. Wall Street analysts on average expect the bank's profits to rise 10.6% this year. Moreover, according to the consensus estimate, BAC's average annual profit increase over the next five years will be 20.7%. The stock fell in 2018 amid a number of headwinds. Among these headwinds were the declining results of its investment banking unit, the negative market environment and fears of an inverted yield curve. However, amid these headwinds, Warren Buffett continues to buy BAC, indicating that the Oracle of Omaha considers it to be one of the best stocks in the market. Also, one can likely assume BAC has become his favorite bank stock. He now has a bigger position in BAC than in Wells Fargo (NYSE:WFC), which used to be his favorite bank stock. Assuming the economy doesn't nose dive, investors can, like Buffett, profit handsomely from one of the best stocks to buy in the market, BAC stock. ### Cheap Stocks to Buy: CannTrust (CNTTF) Although it's not among the more inexpensive stocks in the S&P 500, Canadian cannabis company CannTrust (OTCMKTS:CNTTF) makes the cheap stocks list because it's inexpensive compared to its peers in the marijuana industry. Unlike most cannabis companies, CannTrust is already profitable, and CNTTF stock has a forward price-earnings ratio of about 29.8. In an environment in which an industry leader, Canopy Growth (NYSE:CGC), trades at 100 times its sales, CNTTF is a screaming bargain and one of the best stocks in the market. Canadian marijuana stocks have suffered from a "sell the news" phenomenon since the companies' principal product became fully legal in their home market. However, CannTrust is poised to benefit from many trends. For one, it has applied for a listing on the New York Stock Exchange. Joining the Big Board should open up CNTTF stock to a new class of investors. Secondly, although cannabis remains on the list of Schedule 1 drugs in the U.S., the recent legislation that legalized hemp should give all Canadian marijuana firms a foothold in the U.S. market. The company's focus on pharma also provides the stock with another potential catalyst. CannTrust sent its first shipment of cannabis oil to Denmark in the third quarter of 2018. It has also entered the Asia-Pacific market, through a partnership with Australia-based Cannatrek. Consequently, even if the company fails to meaningfully penetrate the U.S. market, it still can benefit from overseas expansion. Furthermore, even though CannTrust's valuation is lower than that of its major peers, its growth should remain strong for the foreseeable future. On average, analysts predict that its profits will increase by almost 155% this year, making CNTTF a very cheap stock, despite its forward price-earnings ratio of nearly 30. As CannTrust moves into other developed countries and possibly the U.S., a revived interest in cannabis should enable its valuation to catch up with that of its peers. ### Cheap Stocks to Buy: Intel (INTC) Few PC-era stocks have suffered as much as Intel (NASDAQ:INTC) has. Once the world's largest chip maker, Intel stagnated as consumers increasingly turned away from PCs. Intel's PC-era peers such as Microsoft (NASDAQ:MSFT), Nvidia (NASDAQ:NVDA), and even AMD (NASDAQ:AMD) built new business lines and resumed growing. However, INTC stock continued to languish. The high turnover of its top management, as well as security-related issues, also weighed on Intel stock. However, INTC looks ready to again become one of the best stocks to buy in tech. The company has invested heavily in data-center technology. As a result, its Data Center group appears poised to overtake its PC Client group in size over the next few years. Due to Intel's purchase of Mobileye, INTC has become a leader in the autonomous-vehicle market. That, along with the company's Internet of Things (IoT) products, should help INTC stock rise. And as the advent of 5G makes more advanced applications possible, Intel will benefit even more from these trends. INTC is a cheap stock due to its price-earnings multiple. It trades at a forward PE ratio of about 10.6, showing that investors have yet to fully appreciate Intel's comeback. Due to a temporary glut of chips, Intel 's profit growth will be slow this year. However, its profits should resume growing by double-digit percentage rates in 2020. Once investors begin to realize that Intel has resumed a leadership role in the tech industry making it one of the best stocks in the market, it should again command valuations comparable to its peers in big tech. As of this writing, Will Healy is long CNTTF. You can follow Will on Twitter at @HealyWriting. ### More From InvestorPlace * 2 Toxic Pot Stocks You Should Avoid * Top 10 Global Stock Ideas for 2019 From RBC Capital * 10 A-Rated Stocks the Smart Money Is Piling Into * 5 Best Bank ETFs for This Week's Earnings Avalanche Compare Brokers The post 3 Cheap Stocks to Buy (Before They Skyrocket) appeared first on InvestorPlace.
The New York State has granted Canopy Growth Corp. (NYSE: CGC) a license to process and produce hemp. The company plans to invest between $100 million and $150 to establish a hemp industrial park somewhere in the state. Canopy is happy with the current New York political leadership that supports the cannabis business. Canopy Co-CEO […] The post Canopy Growth (NYSE: CGC) to Build $100-150 Hemp Plant in New York appeared first on Market Exclusive.
Cannabis News Cannabis producer FoliuMed has completed the construction of its first greenhouses on a 16-hectare grow site near Bogota, Colombia. In an area spanning 20 soccer fields, FoliuMed will produce over 70 tons of medicinal hemp and cannabis plants in 150 greenhouses. The plants will be processed into oils and sold as pharma-grade ingredients […] The post Cannabis Stock News Daily Roundup January 16 appeared first on Market Exclusive.
At a confirmation hearing Tuesday, attorney general nominee William Barr said that the current system around marijuana laws is 'untenable' and he personally supports prohibiting marijuana across the U.S. But, Barr said that under the current set of laws he would not go after cannabis businesses that comply with state regulations and a rescinded Justice Department memo. After Barr's comments, the ETFMG Alternative Harvest ETF , which includes a basket of the largest pot stocks, fell roughly 3% in 15 minutes. Some of the biggest names in the cannabis sector got a late-session haircut too: Canopy Growth Corp. , closed down 2.8%, Aurora Cannabis Inc. touch a mid-session high of a roughly 11% gain but closed the day down 3.2%. Cronos Group Inc. also experienced a similar trading pattern and closed down 5.2%. The lock-up period for Tilray Inc. expired Tuesday and shares fell 17% in the regular session. The Alternative Harvest ETF closed down 3.2% Tuesday.
SMITHS FALLS, ON , Jan. 15, 2019 /PRNewswire/ - Canopy Growth Corporation ("Canopy Growth" or the "Company") (TSX: WEED) (NYSE: CGC) will release its financial results for the third ...
Avicanna focuses on several product categories, including plant-derived cannabinoid pharmaceuticals, phytotherapeutics, dermacosmetics and extracts. In 2017, Avicanna became the first marijuana company to be accepted into Johnson & Johnson (NYSE: JNJ)'s JLABS @ Toronto, an incubation life science center. Last year, the company acquired controlling interests in Sativa Nativa and Santa Marta Golden Hemp, in which it has 70-percent and 60-percent stakes, respectively.
Canadian cannabis company Canopy Growth Corp (NYSE: CGC ) confirmed Monday that it received a license to produce and process hemp in New York, prompting GMP to turn incrementally bullish on the stock. ...
HENDERSON, NV / ACCESSWIRE / January 15, 2019 / Below are some of the better opportunities on the cannabis market for investors. One we like a lot isn't even technically a cannabis company at all. Clean ...
On Monday, Canopy Growth stock jumped 11% after the Canadian cannabis grower announced that it's coming to the U.S. to produce and process hemp.
CORAL GABLES, FL / ACCESSWIRE / January 15, 2019 / The past week has been extremely exciting for the world of cannabis, and, more specifically, the marijuana industry. Riding out the momentum of last year's monumental legislation, the sector has received much-need notoriety. Next Green Wave Holdings Inc (NXGWF) (NGW), Tilray Inc (TLRY), Innovative Industrial Properities Inc (IIPR), and Canopy Growth Corporation (CGC), (WEED.TO), are 4 pot stocks making headlines this month.
After a late 2018 plunge, cannabis stocks have been on a tear to start 2019 due to a confluence of tailwinds, as I predicted in December. You've had analysts initiate coverage on the industry with a bullish skew. You've had early stage investors talk up the long-term potential of these companies. M&A chatter has picked up and legislation has moved in the right direction. All together, the big four pot stocks -- Canopy Growth (NYSE:CGC), Tilray (NASDAQ:TLRY), Cronos (NASDAQ:CRON) and Aurora (NYSE:ACB) -- are all up more than 30% in 2019 already, and it's not even halfway through January. This trend will persist because 2019 will mark the year that cannabis stocks enter into the U.S. market. The 2018 Farm Bill legalized hemp across America. But, Canadian cannabis companies have had a tough time entering the U.S. market due to cross-border restrictions. Canopy has worked around the restrictions, and was recently awarded a license to process and produce hemp in the state of New York. CGC stock rose 10% in response to the news. InvestorPlace - Stock Market News, Stock Advice & Trading Tips This is more than just a one-off catalyst. The New York State hemp license is the beginning a multi-quarter and multi-year excursion for Canopy into the multi-billion dollar U.S. CBD market. As the company embarks on this excursion, its leadership position will grow, its moat will grow, revenues will grow, profits will grow, visibility will grow and CGC stock will rise. As such, now isn't the time to sell CGC stock. Instead, it's the time to double-down on the long-term bull thesis of Canopy turning into a $100 billion company one day thanks to the global proliferation of legal CBD products, and Canopy's ability to stay at the top of this burgeoning market. ### CGC: Buy the Rumor & Buy the News For contextual purposes, let's provide a timeline of what has transpired over the past few weeks and why CGC stock is up 60% since Dec. 20. First, on Dec. 20, U.S. President Donald Trump signed into law the 2018 Farm Bill, which nationally legalized hemp. In response, Canopy Growth issued a press release commending the U.S. on passing this bill, and saying that Canopy is ready for a U.S. market launch. Roughly two weeks later, Canopy talked about its hemp production potential in Canada, and its desire and capacity to replicate that production in the now legal U.S. market. A few days after that press release, Canopy announced it had received a groundbreaking New York State license to do just that. In other words, the writing has been on the wall since the Farm Bill passed that Canopy was going to enter the U.S. market. Investors sniffed out that a potential licensing deal was in the works, and bid up CGC stock 60% in anticipation of that deal. Yet, even though this was a massive "buy the rumor" rally, you didn't get a typical "sell the news" response. Instead, you got "buy the rumor, buy the news", as CGC stock rose 10% in response to the New York State license news. * 10 Companies That Could Post Decelerating Profits Why? Because the implications of this license are huge, and indeed big enough to keep bulls in control and bears on their heels. ### The U.S. CBD Push Has Begun Canopy isn't just going to produce industrial hemp in New York, and stop there. Instead, this is just the first step of what will turn a multi-year expansion into the multi-billion dollar U.S. hemp market. Thanks to the passing of the Farm Bill, some industry insiders peg this market as measuring in at $22 billion in revenues within the next several years. Canopy's market cap is just $13 billion. Thus, this company is in the very early stages of entering a market that is twice the size of the company. This opportunity comes on top of early stage growth in a Canadian cannabis market that projects to also be a $10 billion market one day. All together, the U.S CBD push from Canopy has begun. It won't stop anytime soon. That means big growth is in store for the company over the next several quarters. Such big growth will keep bulls in control, bears on their heels and the stock on a winning trajectory. As such, the outlook for CGC stock to keep rallying in the near to medium term is quite favorable. ### Canopy Growth Is a $100 Billion Company In The Making The big picture behind CGC stock is that this is a company that is second-to-none in terms of size, innovation, leadership, resources, production capacity and expansion in a rapidly growing global CBD market that projects to be huge one day. There's plenty of reason to believe, given CBD's medicinal and recreational applications and widespread use among younger demographics, that the global CBD market will be as big as the global alcohol and tobacco markets one day. Both of those markets are in the $700 billion to $1 trillion-plus range. Conservatively, let's say the cannabis market maxes out around $500 billion in a decade. Let's also say that Canopy only controls about 5% of the global market, and runs at an alcoholic beverage market average of 30% operating margins. * 7 Video Game Stocks on Steep Discount Back of the envelope calculations produce $25 billion revenue potential and $7.5 billion operating profit potential for CGC within a decade. Taking out 20% for taxes and throwing a market-average 16x multiple on the net profits, one can easily see how CGC stock could be worth nearly $100 billion in a decade. That potential valuation is 10 years away. CGC stock has a market cap of just over $10 billion today. Thus, this is a potential ten-bagger over the next decade. Granted, ten years is a long time, and a lot could happen between now and then. But, a New York State hemp license is a big step in the right direction toward CGC stock realizing its $100 billion potential. ### Bottom Line on CGC Stock A New York State hemp license is big news, and a huge step toward this company maintaining its leadership position in the rapidly growing global CBD market. So long as this company keeps taking steps to defend market share, CGC stock has the potential to turn into a $100 billion company one day. As of this writing, Luke Lango was long CGC and CRON. ### More From InvestorPlace * 2 Toxic Pot Stocks You Should Avoid * 10 Key Emerging-Market Stocks to Buy for Contrarian Investors * 7 Stocks at Risk of the Global Smartphone Slowdown * 7 Pharmaceutical Stocks That Just Raised Prices This Year Compare Brokers The post Why Canopy Growth's Arrival in the U.S. Will Be Huge for CGC Stock appeared first on InvestorPlace.
NEW YORK, NY / ACCESSWIRE / January 15, 2019 / Wall Street extended losses on Monday as concerns of a global economic slowdown were reignited on weaker-than-expected economic data from China. In December, ...